Semaglutide significantly lowers MACCE risk in obese T2DM patients with comorbid rheumatoid arthritis
Background
The presence of Rheumatoid arthritis (RA) often imposes physical limitations, hindering physical activity and weight management, which exacerbates cardiovascular risk through adverse metabolic profiles and chronic inflammation. For obese patients with Type 2 Diabetes Mellitus (T2DM) and RA, this combined burden significantly elevates the risk of major adverse cardiovascular and cerebrovascular events (MACCE). While GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular benefits in other populations, their effectiveness in primary prevention for this specific high-risk cohort, particularly those without established cardiovascular disease, remained underexplored. This study aimed to fill that gap by evaluating semaglutide's impact on MACCE in this vulnerable group.
Study Design
Researchers emulated a target trial using the TriNetX US database, focusing on obese adults (BMI ≥30 kg/m2, aged ≥18 years) with T2DM and comorbid RA, crucially excluding those with prior stroke, heart failure, acute coronary syndrome, or revascularization. A new-user design compared patients initiating semaglutide with those starting non-GLP-1RA second-line glucose-lowering therapies. Propensity-score matching (1:1) balanced baseline covariates. The primary outcome was incident MACCE (composite of all-cause mortality, myocardial infarction, heart failure, or stroke), with secondary outcomes including individual MACCE components and DMARDs escalation. Cox proportional hazards models estimated hazard ratios over up to 2 years of follow-up.
Results
Between Jan 2014 and Jan 2025, the study identified 1,200 patients initiating semaglutide and 2,972 initiating non-GLP-1RA therapies. After propensity-score matching (PS), 1,017 semaglutide users were compared with 1,017 non-GLP-1RA users. Baseline characteristics were well-balanced, with mean age 59.5 vs 59.3 years, 81.3% vs 81.0% women, mean BMI 38.2 vs 38.0 kg/m2, and HbA1c 6.8% vs 7.0% respectively. > Semaglutide initiation was associated with a significantly lower risk of incident major adverse cardiovascular and cerebrovascular events (MACCE) compared with non-GLP-1RA therapies. The abstract did not provide specific hazard ratios or p-values for the primary outcome, but clearly indicated a significant reduction. Secondary outcomes included individual MACCE components, HF hospitalization, and DMARDs escalation, with Bonferroni correction applied for multiple comparisons.
Why It Matters
Semaglutide offers significant primary cardiovascular protection for a particularly high-risk population: obese individuals with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. This real-world evidence expands the known benefits of GLP-1 receptor agonists beyond established cardiovascular disease, suggesting a broader role in comprehensive risk management. Clinicians should consider semaglutide not just for glycemic control or weight loss, but also for its robust capacity to reduce MACCE in these complex patients. This finding supports integrating cardiovascular risk reduction more explicitly into treatment paradigms for individuals with multiple cardiometabolic and inflammatory comorbidities, potentially shifting towards earlier and more aggressive primary prevention strategies.